68Ga-OncoFAP (Imaging)

68Ga-OncoFAP is a small molecule radiotracer with ultra high affinity for Fibroblast Activation Protein (FAP). The product is suitable for the non-invasive detection of a variety of metastatic solid tumors, as FAP is overexpressed in more than 90% of epithelial cancers (e.g., malignant breast, colorectal, ovarian, lung, skin, prostate and pancreatic cancers, as well as in some soft tissue and bone sarcomas).

68Ga-OncoFAP consists of (i) a small organic ligand targeting FAP, (ii) an innovative spacer structure and (iii) a DOTAGA chelator for the incorporation of 68Gallium.

68Ga-OncoFAP displays best-in-class performance both in vitro and in vivo with the highest reported affinity to the FAP antigen. In preclinical models of cancer, the product has shown a rapid and selective accumulation in the tumor mass with an extraordinarily low kidney uptake.

The exceptional targeting activity of 68Ga-OncoFAP has been confirmed by PET scans in more than 100 patients with a variety of solid tumors.

For more information, please see “ ongoing clinical trials”.
ONGOING CLINICAL TRIALS
  • OncoFAP-68Ga has recently entered in a first-in-man imaging study in patients with advanced solid cancers
  • Additional studies with OncoFAP-68Ga (Imaging) and OncoFAP-177Lu (Therapy) are about to start
ONGOING CLINICAL TRIALS

      • 68Ga-OncoFAP is currently studied in a first-in-human imaging study in patients with advanced solid cancers (NCT05784597)

References

Puglioli et al. (2022) Chem, doi: 10.1016/j.chempr.2022.10.006

–

Galbiati et al. (2022) J Nucl Med, numed.122.264036

–

Backhaus et al. (2021) Eur J Nucl Med Mol Imaging, 10.21203/rs.3.rs-969176/v1

–

Millul et al. (2021) PNAS, 118, 16, e2101852118